CAMTA1 divergent transcript (CAMTA1-DT)

CAMTA1 divergent transcript (CAMTA1-DT), also known as lncCAMTA1 or CAMTA1-AS1, is a long non-coding RNA (lncRNA) transcribed divergently from the CAMTA1 gene locus[5]. lncCAMTA1 regulates gene expression at the post-transcriptional level through interactions with microRNAs, notably acting as a molecular sponge for miR-20b, thereby modulating downstream targets such as vascular endothelial growth factor (VEGF)[1]. In breast cancer cell lines, CAMTA1-DT/lncCAMTA1 promotes cell proliferation and motility, and its knockdown induces apoptosis, apparently via regulation of apoptosis-associated proteins and inhibition of key signaling pathways (such as MAPK/ERK and JAK/STAT3)[1]. While lncCAMTA1 is not classified as a classical therapeutic target like an enzyme or receptor, it is increasingly studied for its putative role in cancer pathogenesis and as a potential biomarker or novel therapeutic target[1][5]. No drugs are currently known to directly target CAMTA1-DT. **Note:** The referenced major research article on lncCAMTA1’s function in breast cancer has been retracted[1]; this may impact the reliability of some specific functional claims, but the nomenclature and general classification as a divergent lncRNA remain correct.

Other names

lncCAMTA1CAMTA1-AS1

Not applicable (no known direct-acting drugs); acts as competing endogenous RNA (ceRNA) for microRNA (miR-20b); regulatory effects on VEGF signaling and MAPK/ERK, JAK/STAT3 pathways